Why are cancer drugs so expensive in the United States, and what are the solutions?

Mayo Clinic Proceedings
Hagop Kantarjian, S Vincent Rajkumar

Abstract

High cancer drug prices are a worsening trend in cancer care and are affecting patient care and our health care system. In the United States, the average price of cancer drugs for about a year of therapy increased from $5000 to $10,000 before 2000 to more than $100,000 by 2012, while the average household income has decreased by about 8% in the past decade. Further, although 85% of cancer basic research is funded through taxpayers' money, Americans with cancer pay 50% to 100% more for the same patented drug than patients in other countries. Bound by the Hippocratic Oath, oncologists have a moral obligation to advocate for affordable cancer drugs. In this article, we discuss the high cost of cancer drugs, the reasons for these high prices, the implications for patients and the health care system, and potential solutions to the problem.

References

Oct 22, 2005·BMJ : British Medical Journal·Donald W Light, Joel Lexchin
Apr 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce E Hillner, Thomas J Smith
Sep 16, 2011·Health Policy·Ellen Nolte, Martin McKee
Oct 6, 2012·Mayo Clinic Proceedings·Mustaqeem Siddiqui, S Vincent Rajkumar
May 8, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianLeonard A Zwelling
Jun 8, 2013·Cancer·Hagop KantarjianLeonard Zwelling
Sep 5, 2013·Cancer·Donald W Light, Hagop Kantarjian
Sep 6, 2013·The New England Journal of Medicine·Hans V Hogerzeil
Dec 25, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stacie B DusetzinaNancy L Keating
Aug 29, 2014·JAMA : the Journal of the American Medical Association·Lori FrankUNKNOWN Patient-Centered Outcomes Research Institute

❮ Previous
Next ❯

Citations

Mar 6, 2016·Mayo Clinic Proceedings·Andrea MessoriSabrina Trippoli
Aug 8, 2015·Cancer·Jagpreet ChhatwalHagop M Kantarjian
Jul 28, 2015·Mayo Clinic Proceedings·Ayalew TefferiCharles A LeMaistre
Dec 22, 2015·The Lancet. Haematology·Scott F HuntingtonEdward A Stadtmauer
Jun 24, 2015·Cancer·Jagpreet ChhatwalHagop Kantarjian
Jul 5, 2015·Mayo Clinic Proceedings·S Vincent Rajkumar, Manish Kohli
Jul 15, 2016·Lancet·Philippe Moreau, S Vincent Rajkumar
Jul 30, 2016·Frontiers in Oncology·Natalie J Serkova, S Gail Eckhardt
Oct 4, 2016·The Lancet. Haematology·Guillermo J Ruiz-Argüelles, David P Steensma
Nov 8, 2016·The Lancet Oncology·Y Tony YangCharles L Bennett
Nov 25, 2016·British Journal for the History of Science·Joseph M Gabriel
Oct 16, 2016·Blood·S Vincent Rajkumar, Jean Luc Harousseau
Feb 10, 2017·Cancer·Hagop Kantarjian, Yogin Patel
Oct 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan R R LewisWendy Lipworth
May 5, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ya-Chen Tina ShihFabrice Smieliauskas
Oct 27, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew BerchuckLaura J Havrilesky
Feb 11, 2018·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Maryann Mazer-AmirshahiLewis S Nelson
Dec 1, 2017·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Maryann Mazer-AmirshahiLewis S Nelson
Jul 12, 2018·Journal of Medical Economics·Panagiotis Petrou
Sep 16, 2018·American Journal of Hematology·Hagop KantarjianVivian Ho
Oct 26, 2018·Journal of Oncology Practice·Thomas G KnightGrant R Williams
Jan 2, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Bernard L MariniAnthony J Perissinotti
Sep 13, 2019·Journal of General Internal Medicine·Cecilie Goltermann ToxværdNanna Borup Johansen
Oct 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Noa GordonDaniel A Goldstein
Oct 11, 2017·Journal of Oncology Practice·Jonathan FooteLaura J Havrilesky
Apr 3, 2020·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Nov 2, 2019·Journal of the National Cancer Institute·K Robin YabroffCarrie N Klabunde
Apr 5, 2017·MMW Fortschritte der Medizin·Martin C Michel
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Rafael Fonseca, Jennifer Hinkel
Jul 30, 2020·Medicina·Maria Isabella DoneganiSilvia Morbelli
Dec 21, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Maria J De HerdtLeendert H Looijenga
Apr 2, 2020·Health Care Analysis : HCA : Journal of Health Philosophy and Policy·Fanor BalderramaChristopher J Longo
Jun 25, 2020·Blood Cancer Journal·S Vincent Rajkumar
Sep 13, 2017·The Milbank Quarterly·Olivier J WoutersMartin McKEE
Sep 21, 2018·American Society of Clinical Oncology Educational Book·S Vincent Rajkumar
May 13, 2018·PharmacoEconomics·T Joseph MattinglyEleanor M Perfetto
May 20, 2016·Cancer Research·Alberto OcanaIan F Tannock
Jan 7, 2020·Mayo Clinic Proceedings·S Vincent Rajkumar
Oct 15, 2020·Annals of Surgical Oncology·Anaeze C OffodileCharles Butler
May 6, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Panagiotis Petrou

❮ Previous
Next ❯

Related Concepts

Related Feeds

AIDS Malignancies (ASM)

HIV infection increases the risk of non-communicable diseases common in the aged, including cardiovascular disease, neurocognitive decline, non-aids malignancies, osteoporosis, and frailty. Discover the latest research in AIDS malignancies.

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.

Related Papers

Folia clínica internacional
J GOTTLIEB
The Medical Journal of Australia
N E Kirkwood
© 2021 Meta ULC. All rights reserved